Hepatic arterial infusion chemotherapy plus regorafenib compared with regorafenib alone as second-line therapy for advanced hepatocellular carcinoma: a randomised controlled trial protocol
Introduction The exact role of hepatic arterial infusion chemotherapy (HAIC) in advanced hepatocellular carcinoma (aHCC) is still unknown. The combination of HAIC and sorafenib has been proven to be more effective than sorafenib alone in the first-line treatment of aHCC. The aim of the study is to e...
Saved in:
| Main Authors: | Wei Sun, Xiao Li, Tao Gong, He Zhao, Xiaowu Zhang, Pengfei Tian, Yingen Luo, Jingui Li, Zhengqiang Yang, Peng Song |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMJ Publishing Group
2024-12-01
|
| Series: | BMJ Open |
| Online Access: | https://bmjopen.bmj.com/content/14/12/e080805.full |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Effcacy and toxicity of regorafenib compared to reintrodaction of chemotherapy in metastatic colon cancer: retrospective multicenter study
by: E. S. Kuzmina, et al.
Published: (2023-09-01) -
Synergistic effect of regorafenib with aminoglycosides in ferroptosis-mediated liver injury
by: Maha Raja Dahar, et al.
Published: (2025-07-01) -
Long-lasting remission in a metastatic hepatocellular carcinoma patient after combined regorafenib therapy and surgery
by: Elisabetta Goio, et al.
Published: (2020-09-01) -
Effect of Electric Fields on the Mechanical Mechanism of Regorafenib–VEGFR2 Interaction to Enhance Inhibition of Hepatocellular Carcinoma
by: Yichen Tian, et al.
Published: (2025-01-01) -
EPHX1 enhances drug resistance to regorafenib by activating the JAK/STAT signaling pathway in hepatocellular carcinoma cell lines
by: Bin Xu, et al.
Published: (2025-07-01)